North Carolina Biotechnology Center

Atlantic Fish Company is focused on producing cultivated seafood through cellular agriculture, operating from its headquarters in Raleigh-Durham, North Carolina. The company aims to provide sustainable seafood options by cultivating fish in a controlled environment. This innovative approach allows Atlantic Fish Company to offer fresh fish meat that maintains the natural taste while minimizing the environmental impact associated with traditional fishing practices. By leveraging cellular agriculture, the company seeks to meet the growing demand for sustainable protein sources.

Qatch Technologies is focused on creating innovative tools to assess the injectability and manufacturability of biopharmaceutical products. The company has developed a proprietary pre-screening technology that integrates microfluidics and acoustics, allowing for the precise measurement of viscosity using minimal liquid volumes. This advanced technology enables biopharmaceutical researchers to identify suitable injectable formulations at early stages of development, thereby streamlining the process of selecting optimal molecules for further study. By addressing potential manufacturing challenges related to viscosity, Qatch Technologies aims to enhance the efficiency and effectiveness of drug development in the biopharmaceutical sector.

Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.

Avior Bio is a clinical-stage pharmaceutical company focused on developing innovative treatments for neurological conditions and pruritus in patients with liver disease. The company utilizes its proprietary Speedit™ Transmucosal Film Technology, which allows for effective drug delivery by bypassing first-pass metabolism and minimizing the production of glucuronide metabolites excreted by the kidneys. This technology aims to provide significant relief from various symptoms, including insomnia, anxiety, depression, and excoriation. With a strong management team, an experienced advisory board, and dedicated scientists, Avior Bio is well-positioned to deliver safe and effective therapeutic solutions to improve patient outcomes.

Duke University is a private research university located in Durham, North Carolina. With approximately 15,000 students and a renowned faculty, Duke is dedicated to pushing the boundaries of knowledge and making a positive impact on society. The university's Office of News and Communications, along with Duke Web Services, played a key role in developing the university's web presence, collaborating with Viget Labs to create a cohesive design. Duke offers free tools to help members of the community align their websites with the university's branding, including messaging and style guidelines, color palettes, typefaces, web templates, and information on using the "Duke brand bar." For further details, individuals can refer to the online style guide or reach out to Duke Web Services for assistance.

InSoma Bio integrates biology and materials science to solve problems in tissue engineering and regenerative medicine. It offers genetically engineer protein-based materials that can mimic the naturally found elastin found in extracellular tissues. The company also offers reconstructive plastic surgeries and injectable materials.

Amalgent Therapeutics is a clinical-stage company based in Chapel Hill, North Carolina, focused on developing innovative oral pain management drugs. Founded in 2020, the company specializes in combination therapies that significantly lower the doses needed for effective analgesia while minimizing side effects. This approach aims to enhance the efficacy of pain management for healthcare professionals, allowing them to provide safer and more effective oral therapeutics to patients.

InGateyGen is an agricultural biotechnology company focused on developing and producing hypoallergenic or allergen-reduced peanuts. Utilizing proprietary technologies such as genomics, proteomics, plant tissue culture, and plant propagation, the company aims to create high-value agricultural products that enhance consumer safety and well-being. InGateyGen's commitment to innovation in food science seeks to address the growing demand for allergen-free options, ultimately contributing to improved health outcomes for individuals with peanut allergies.

Lacuna Medical has created a 3D shape catheter that is more resistant to catheter failure. The 3D shape protection uses memory shape to the protect the proximal holes of the catheter.

North Carolina State University, located in Raleigh, North Carolina, is a prominent educational institution established in 1887. It offers a diverse range of academic programs, granting 106 bachelor's degrees, 104 master's degrees, 61 doctoral degrees, and a Doctor of Veterinary Medicine. The university is renowned for its strengths in science, technology, engineering, and mathematics, as well as in fields such as agriculture and life sciences. It is part of the University of North Carolina system, which encompasses 17 campuses statewide, and serves over 220,000 students. NC State has a significant research presence at the North Carolina Research Campus, focusing on food crops and sustainability. To address environmental concerns, the university launched the University Sustainability Office in 2008. The university is governed by a board of trustees that oversees its assets and operations.

The University of North Carolina at Chapel Hill, established in 1789, is the first public university in the United States and operates as a non-profit educational institution. It is dedicated to teaching, research, and public service, serving a diverse community of undergraduate, graduate, and professional students. The university's mission is to foster scholarship and creativity while preparing future leaders to contribute positively to society. With a strong commitment to excellence, it leverages the expertise of its faculty and staff to enhance access to education and promote the success of its students. Additionally, the university manages an endowment fund that supports various initiatives, including scholarships, fellowships, professorships, and research across multiple disciplines. Through its outreach efforts, UNC Chapel Hill aims to improve the quality of life for the citizens of North Carolina and beyond.

North Carolina Central University (NCCU), established in 1910, is a historically black college located in Durham, North Carolina. It has built a strong reputation for its commitment to academic excellence, research, and cultural awareness. NCCU offers over 100 programs across nearly 30 academic departments, providing both undergraduate and graduate degrees. Notable offerings include unique programs such as a master’s degree in Jazz Studies and a bachelor’s degree in Apparel Design, alongside joint graduate programs in law and business. The university actively promotes diversity, welcoming students of all races and ethnicities, and provides various financial aid options, including institutional scholarships and need-based government programs. With a focus on preparing students for success in a global marketplace, NCCU continues to play a vital role in higher education and community development.

Belhaven Biopharma is focused on developing life-saving medications for the treatment of anaphylaxis. The company specializes in the scale-up and production of clinical trial materials, as well as the preparation and filing of Investigational New Drug applications. It is currently conducting a pilot human clinical trial for its innovative dry powder intranasal epinephrine, which is designed to offer a convenient, safe, and rapid treatment option during emergency situations. By developing a portfolio of dry powder nasal medications, Belhaven Biopharma aims to enhance patient access to timely treatment in critical moments.

North Carolina State University, located in Raleigh, North Carolina, is a prominent educational institution established in 1887. It offers a diverse range of academic programs, granting 106 bachelor's degrees, 104 master's degrees, 61 doctoral degrees, and a Doctor of Veterinary Medicine. The university is renowned for its strengths in science, technology, engineering, and mathematics, as well as in fields such as agriculture and life sciences. It is part of the University of North Carolina system, which encompasses 17 campuses statewide, and serves over 220,000 students. NC State has a significant research presence at the North Carolina Research Campus, focusing on food crops and sustainability. To address environmental concerns, the university launched the University Sustainability Office in 2008. The university is governed by a board of trustees that oversees its assets and operations.

The University of North Carolina at Greensboro, also known as UNCG and UNC Greensboro, is a public coeducational and research university in Greensboro in North Carolina in the United States of America, and it is a constituent institution of the system of the University of North Carolina. However, the University of North Carolina at Greensboro is a stand-alone university and awards its own degrees like all members of the system of the University of North Carolina . The Southern Association of Colleges and Schools Commission on Colleges accredits the University of North Carolina at Greensboro to award baccalaureate, masters, specialist, and doctoral degrees.

The University of North Carolina at Chapel Hill, established in 1789, is the first public university in the United States and operates as a non-profit educational institution. It is dedicated to teaching, research, and public service, serving a diverse community of undergraduate, graduate, and professional students. The university's mission is to foster scholarship and creativity while preparing future leaders to contribute positively to society. With a strong commitment to excellence, it leverages the expertise of its faculty and staff to enhance access to education and promote the success of its students. Additionally, the university manages an endowment fund that supports various initiatives, including scholarships, fellowships, professorships, and research across multiple disciplines. Through its outreach efforts, UNC Chapel Hill aims to improve the quality of life for the citizens of North Carolina and beyond.

The University of North Carolina Wilmington, the state's coastal university, is dedicated to the integration of teaching and mentoring with research and service. University of North Carolina Wilmington, commitment to student engagement, creative inquiry, critical thinking, thoughtful expression and responsible citizenship is expressed in our baccalaureate and master's programs, as well as doctoral programs in areas of expertise that serve state needs. Our culture reflects our values of diversity and globalization, ethics and integrity, and excellence and innovation.

Sigma Xi is an international honor society for scientists and engineers. It also provides grants annually to promising young researchers and sponsors a variety of programs supporting ethics in research, science, and engineering education.

University of North Carolina at Asheville is a co-educational, four year, public liberal arts university.

Coprata is a digital health and technology company that offers innovative solutions for monitoring gut health through stool analysis and artificial intelligence. By enabling hands-free stool sampling and automated monitoring of bowel movements during regular toilet use, Coprata provides individuals with valuable insights into their gut health. This service allows users to track the effects of their lifestyle choices and receive early warnings about potential changes in their gut health. The platform aims to facilitate the detection and management of both acute and chronic gastrointestinal diseases, as well as infectious diseases. Additionally, Coprata is focused on developing non-invasive methods for health monitoring that seamlessly integrate into daily routines, ultimately enhancing personalized wellness and health management.

Enzerna Biosciences is a biotechnology company based in Morrisville, North Carolina, specializing in gene therapy solutions. The company focuses on addressing nucleotide expansion disorders by utilizing Artificial Site-Specific RNA Endonucleases (ASREs). These engineered proteins are designed to target and eliminate toxic RNA molecules responsible for these disorders, offering a potential long-term curative approach. Enzerna's innovative RNA editing technology and related products aim to provide effective treatments for genetic diseases.

Oncotect is a Raleigh-based biotech startup focused on the early detection of cancer risks in dogs through a novel urine-based screening test. The company has developed a patent-pending in-vitro diagnostic platform that utilizes proprietary technology alongside the olfactory receptors of C. elegans to identify cancerous volatile metabolites in dog urine. This innovative method provides a non-invasive, convenient, and affordable approach to multi-cancer screening, making it the only test of its kind available for dogs. By enabling dog owners to detect potential cancer risks early, Oncotect aims to improve canine health outcomes and enhance the ability to manage cancer in pets.

UNC Charlotte is North Carolina's urban research university. It leverages its location in the state's largest city to offer internationally competitive programs of research and creative activity, exemplary undergraduate, graduate and professional programs, and a focused set of community engagement initiatives. UNC Charlotte maintains a particular commitment to addressing the cultural, economic, educational, environmental, health, and social needs of the greater Charlotte region.

Plakous Therapeutics, based in Winston-Salem, North Carolina, specializes in producing restorative and regenerative healing products derived from post-delivery human placentas. Founded in 2016 by Seth Tomblyn and Scott Washburn, the company manufactures biotherapeutics, including its flagship product, Protego-PD, an orally delivered acellular therapy. Plakous Therapeutics focuses on utilizing placental cytokines and growth factors to create allografts that promote and support the body's natural healing processes. By enhancing the functionality of the amniotic membrane as a drug delivery device, the company aims to provide healthcare providers and patients with effective therapeutic options grounded in scientific research and clinical evidence.

Plakous Therapeutics, based in Winston-Salem, North Carolina, specializes in producing restorative and regenerative healing products derived from post-delivery human placentas. Founded in 2016 by Seth Tomblyn and Scott Washburn, the company manufactures biotherapeutics, including its flagship product, Protego-PD, an orally delivered acellular therapy. Plakous Therapeutics focuses on utilizing placental cytokines and growth factors to create allografts that promote and support the body's natural healing processes. By enhancing the functionality of the amniotic membrane as a drug delivery device, the company aims to provide healthcare providers and patients with effective therapeutic options grounded in scientific research and clinical evidence.

Renaissance Fiber produces high-quality fiber from domestically sourced industrial hemp using proprietary methods that are clean (Ecologically Invisible™), inexpensive, and scalable. Our material is suitable for a wide range of applications in textiles and technical fibers.

Coprata is a digital health and technology company that offers innovative solutions for monitoring gut health through stool analysis and artificial intelligence. By enabling hands-free stool sampling and automated monitoring of bowel movements during regular toilet use, Coprata provides individuals with valuable insights into their gut health. This service allows users to track the effects of their lifestyle choices and receive early warnings about potential changes in their gut health. The platform aims to facilitate the detection and management of both acute and chronic gastrointestinal diseases, as well as infectious diseases. Additionally, Coprata is focused on developing non-invasive methods for health monitoring that seamlessly integrate into daily routines, ultimately enhancing personalized wellness and health management.

Plakous Therapeutics, based in Winston-Salem, North Carolina, specializes in producing restorative and regenerative healing products derived from post-delivery human placentas. Founded in 2016 by Seth Tomblyn and Scott Washburn, the company manufactures biotherapeutics, including its flagship product, Protego-PD, an orally delivered acellular therapy. Plakous Therapeutics focuses on utilizing placental cytokines and growth factors to create allografts that promote and support the body's natural healing processes. By enhancing the functionality of the amniotic membrane as a drug delivery device, the company aims to provide healthcare providers and patients with effective therapeutic options grounded in scientific research and clinical evidence.

Kepley BioSystems is focused on developing innovative technologies aimed at addressing significant challenges in both marine and healthcare sectors. The company offers ocean restorative technology designed to combat the depletion of wild fish populations, promoting sustainable practices in marine ecosystems. Additionally, Kepley BioSystems is advancing life science solutions that provide accurate methods for testing dangerous endotoxins. Their platform focuses on healthcare innovations, specifically in the detection of blood-borne pathogens, enabling physicians to deliver rapid and sensitive diagnostics for bloodstream infections. Through these efforts, Kepley BioSystems aims to contribute to environmental sustainability and improve health outcomes.

The Company is focused on the commercialization of its first oncology application: treatment of advanced hepatocellular carcinoma. It has completed a phase II study, which shows effectiveness as well as excellent tolerability, even in previously treated patients with severely impaired liver function. See less

North Carolina State University, located in Raleigh, North Carolina, is a prominent educational institution established in 1887. It offers a diverse range of academic programs, granting 106 bachelor's degrees, 104 master's degrees, 61 doctoral degrees, and a Doctor of Veterinary Medicine. The university is renowned for its strengths in science, technology, engineering, and mathematics, as well as in fields such as agriculture and life sciences. It is part of the University of North Carolina system, which encompasses 17 campuses statewide, and serves over 220,000 students. NC State has a significant research presence at the North Carolina Research Campus, focusing on food crops and sustainability. To address environmental concerns, the university launched the University Sustainability Office in 2008. The university is governed by a board of trustees that oversees its assets and operations.

The University of North Carolina Wilmington, the state's coastal university, is dedicated to the integration of teaching and mentoring with research and service. University of North Carolina Wilmington, commitment to student engagement, creative inquiry, critical thinking, thoughtful expression and responsible citizenship is expressed in our baccalaureate and master's programs, as well as doctoral programs in areas of expertise that serve state needs. Our culture reflects our values of diversity and globalization, ethics and integrity, and excellence and innovation.

Appalachian State University, located in Boone, North Carolina, provides a comprehensive educational experience with over 170 undergraduate and graduate degree programs. The university offers diverse majors, including Actuarial Science, Archaeology, Nursing, and Theatre Arts, emphasizing both academic rigor and cultural enrichment. In addition to its academic offerings, Appalachian State hosts a variety of cultural activities such as concerts, literary readings, and theatre productions, along with events like a Summer Arts festival and a performing arts series. The university is selective in its admissions process, with a competitive average GPA of 3.94 and SAT score of 1141 among incoming students. Financial aid is available through institutional scholarships based on academic merit and extracurricular involvement, as well as federal aid options. The Appalachian State University Foundation, a non-profit organization, supports students through scholarships and academic program funding.

EncepHeal Therapeutics, Inc., based in Winston-Salem, North Carolina, specializes in developing therapeutic agents aimed at treating mental health disorders and substance use disorders. Founded in 2015, the company focuses on creating non-addictive medications as alternatives for individuals struggling with addiction to substances such as cocaine and methamphetamine. EncepHeal Therapeutics is committed to guiding its innovative psychostimulant addiction therapeutics through clinical trials, ensuring they are safe, effective, and affordable. The company's mission is to improve the lives of those affected by addiction and other mental health conditions by providing accessible treatment options.

North Carolina A&T State University is so many things to so many people, both in our state and around the country. North Carolina A&T State University is an HBCU. We are a top-flight research university, the largest historically black university (HBCU) in the country, the #1 producer of degrees awarded to African Americans in North Carolina and nationally recognized or our excellence in science, technology, mathematics and engineering (STEM) education. We are a diverse community, bound by intense pride and tradition, with fiercely loyal alumni who hold positions of importance and influence in companies and government agencies across the state, the country and the world. We are achievers, driven by a curious, limitless, fearless spirit that fuels discovery and innovation, resulting in 41 patents issued based on our research, as well as numerous spin-off and start-up companies. We are inclusive and welcoming, with students from many backgrounds and cultures, every part of our state, our nation and countries around the globe. We are passionate, driven by a desire to do more, be more and make more of a difference. Since we opened our doors in 1892, we have focused on giving every student the hands-on opportunities, core knowledge and global perspective that will lead them to make real and lasting change in their lives and the lives of others. At N.C. A&T, we have so much to be proud of, and you can learn more about those "Points of Pride" here. You can also use the links below to learn more about what makes N.C. A&T unique, from our leadership and history to our many rankings and recognitions.

RainBIO is a pioneering company in the field of ocular gene therapy, specifically targeting corneal blindness. The company has developed an innovative adeno-associated virus (AAV) vector gene therapy designed to reverse and prevent blindness by directly improving corneal cellular function. This therapy aims to assist patients who are at risk of losing their eyesight due to various ocular conditions, enabling them to maintain or restore their vision. RainBIO's approach represents a significant advancement in the treatment of corneal diseases, offering hope to individuals facing the threat of blindness.

The University of North Carolina at Chapel Hill, established in 1789, is the first public university in the United States and operates as a non-profit educational institution. It is dedicated to teaching, research, and public service, serving a diverse community of undergraduate, graduate, and professional students. The university's mission is to foster scholarship and creativity while preparing future leaders to contribute positively to society. With a strong commitment to excellence, it leverages the expertise of its faculty and staff to enhance access to education and promote the success of its students. Additionally, the university manages an endowment fund that supports various initiatives, including scholarships, fellowships, professorships, and research across multiple disciplines. Through its outreach efforts, UNC Chapel Hill aims to improve the quality of life for the citizens of North Carolina and beyond.

Belhaven Biopharma is focused on developing life-saving medications for the treatment of anaphylaxis. The company specializes in the scale-up and production of clinical trial materials, as well as the preparation and filing of Investigational New Drug applications. It is currently conducting a pilot human clinical trial for its innovative dry powder intranasal epinephrine, which is designed to offer a convenient, safe, and rapid treatment option during emergency situations. By developing a portfolio of dry powder nasal medications, Belhaven Biopharma aims to enhance patient access to timely treatment in critical moments.

East Carolina University (ECU) is a public doctoral/research institution located in Greenville, North Carolina. Founded in 1907 and formerly known as East Carolina Teachers College, it became East Carolina University in 1951. ECU offers a wide range of undergraduate, graduate, and doctoral programs across various fields, including health sciences, medicine, nursing, music, fine arts, communication, technology, and business. The university is distinguished by its Brody School of Medicine, which ranks highly for its emphasis on primary care and rural medicine. Additionally, ECU provides distance education courses to cater to a diverse student population. The East Carolina University Foundation, established in 1963, manages an endowment fund aimed at enhancing the university's academic programs, research activities, and overall student experience.

NabGen, Inc., based in North Carolina, is a biotechnology company specializing in the development of a novel antibody suppression platform. Its primary focus is to overcome a significant challenge in gene therapy: patient-derived anti-drug antibodies that hinder the delivery of adeno-associated virus (AAV) based therapeutics. NabGen aims to ensure all patients can benefit from gene therapy treatments by enabling successful administration to those with pre-existing vector immunity and creating redosing opportunities. The company's innovative protein-based approach acts as a universal antibody suppressant, broadly targeting and blocking various antibody types, including neutralizing antibodies against any therapeutic vector. This technology allows for successful vector-mediated gene delivery without immunocompromising patients, thereby unlocking the full potential of cutting-edge treatments.

UNC Charlotte is North Carolina's urban research university. It leverages its location in the state's largest city to offer internationally competitive programs of research and creative activity, exemplary undergraduate, graduate and professional programs, and a focused set of community engagement initiatives. UNC Charlotte maintains a particular commitment to addressing the cultural, economic, educational, environmental, health, and social needs of the greater Charlotte region.

Helixomer is a company focused on designing and creating functional nucleic acid nanostructures for applications in human health. The company specializes in developing innovative solutions such as RNA-based anticoagulants and their specific reversal agents, utilizing a thrombin inhibitor and antidote. By advancing the field of nucleic acid technology, Helixomer aims to provide effective alternatives to traditional therapies, including potential antibody replacements.

Drive Therapeutics is a biotechnology company focused on enhancing treatments for retinal diseases. The company is developing therapeutics specifically aimed at addressing wet age-related macular degeneration and diabetic retinopathy, including diabetic macular edema. Through its innovative approach, Drive Therapeutics aims to provide more effective solutions for patients suffering from these serious eye conditions.

Apie Therapeutics specializes in the development and commercialization of innovative drug therapies that target the Apelin Receptor biased agonist, focusing on the Apelinergic System. The company aims to pioneer anti-fibrosis therapies that address microvascular diseases by leveraging the Apelin/APJ signaling pathway, which plays a crucial role in protective and post-injury repair mechanisms. By activating this signaling path in endothelial organs, Apie Therapeutics seeks to enhance treatment options for patients suffering from pulmonary, cardiovascular, and metabolic diseases, ultimately improving their quality of life.

CasTag Biosciences is focused on advancing cell biology and regenerative medicine through innovative tools that enhance the analysis of endogenous proteins. By developing adeno-associated virus kits, the company aims to expedite scientific discovery and empower researchers to investigate novel genes across various experimental models. Utilizing a unique two-vector, clustered regularly interspaced short palindromic repeats-based gene editing technique known as homology-independent universal genome engineering, CasTag's products enable the modification of entire panels of proteins within cells and tissues, thereby facilitating a deeper understanding of biological processes.

Avior Bio is a clinical-stage pharmaceutical company focused on developing innovative treatments for neurological conditions and pruritus in patients with liver disease. The company utilizes its proprietary Speedit™ Transmucosal Film Technology, which allows for effective drug delivery by bypassing first-pass metabolism and minimizing the production of glucuronide metabolites excreted by the kidneys. This technology aims to provide significant relief from various symptoms, including insomnia, anxiety, depression, and excoriation. With a strong management team, an experienced advisory board, and dedicated scientists, Avior Bio is well-positioned to deliver safe and effective therapeutic solutions to improve patient outcomes.

North Carolina State University, located in Raleigh, North Carolina, is a prominent educational institution established in 1887. It offers a diverse range of academic programs, granting 106 bachelor's degrees, 104 master's degrees, 61 doctoral degrees, and a Doctor of Veterinary Medicine. The university is renowned for its strengths in science, technology, engineering, and mathematics, as well as in fields such as agriculture and life sciences. It is part of the University of North Carolina system, which encompasses 17 campuses statewide, and serves over 220,000 students. NC State has a significant research presence at the North Carolina Research Campus, focusing on food crops and sustainability. To address environmental concerns, the university launched the University Sustainability Office in 2008. The university is governed by a board of trustees that oversees its assets and operations.

Chiesi USA is a pharmaceuticals company that specializes in research and development services aimed at addressing respiratory, inflammatory, and critical care diseases. The company is dedicated to the discovery, development, and commercialization of products specifically designed to treat conditions such as asthma and other critical care ailments. By focusing on the regulation of the body's inflammatory response, Chiesi USA aims to enhance therapeutic options within the pharmaceutical industry.

Lindy Biosciences, LLC is a development-stage company based in Durham, North Carolina, specializing in protein-based therapeutic formulations. Utilizing a technology known as microglassification, the company gently removes a significant portion of water from solutions of proteins and other biologics, resulting in solid, spherical, amorphous microbeads. These microbeads create stable, dense particles of therapeutic proteins suitable for various applications, including high-concentration injectable suspensions, encapsulation for controlled release, and long-term storage. Established in 2016, Lindy Biosciences aims to provide innovative solutions for the formulation of protein therapeutics, addressing the needs of medical researchers in developing advanced therapeutic options.

Locus Biosciences is a biotechnology company focused on developing a CRISPR-engineered precision antibacterial platform aimed at transforming the treatment of bacterial diseases. The company integrates the antibacterial capabilities of CRISPR-Cas3 technology with the effective and safe delivery of bacteriophages, which are viruses that specifically target bacteria. This innovative approach allows for rapid initiation of treatment by physicians, leading to improved medical outcomes for patients. Through its advanced platform, Locus Biosciences seeks to address the challenges posed by pathogenic bacteria in a precise and targeted manner.

Isolere Bio is a biotechnology company dedicated to simplifying the purification of biotherapeutics, particularly monoclonal antibodies and Adeno-Associated Viruses (AAV). Co-founded with the aim of enhancing global access to essential drugs, Isolere Bio develops innovative manufacturing technologies that utilize a straightforward Tangential Flow Filtration (TFF) setup. This approach facilitates a seamless transition from laboratory-scale processes to large-scale industrial production, thereby improving efficiency within the bioprocessing industry. As monoclonal antibodies continue to gain prominence as effective therapeutics and important research tools, Isolere Bio's work plays a crucial role in advancing the development of new diagnostics and treatments.

Higgs Boson Health is a digital health company focused on enhancing the well-being of individuals undergoing acute interventional or surgical procedures. The company has developed a healthcare mobile application that facilitates seamless communication and engagement among patients, doctors, and hospitals. This application aims to improve patient outcomes and operational efficiencies by enabling effective management of activities related to surgeries and medical procedures. By empowering all stakeholders in the healthcare process, Higgs Boson Health strives to support healthier lives for patients during critical medical interventions.

PRA Health Sciences, established in 1976 and headquartered in Raleigh, North Carolina, is a leading global contract research organization (CRO). It offers comprehensive outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. PRA's extensive services span clinical research, including product registration, early development, and strategic solutions, as well as data solutions such as market intelligence, consulting, and technology-enabled products. With over 17,000 employees across 90 offices in six continents, PRA has supported more than 3,800 clinical trials and contributed to the approval of over 85 products since 2000. The company is known for its commitment to excellence and high-quality global service.

Virokine Therapeutics is a Biotechnology company.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

BiomedInnovations is a medical device company that makes precision air and fluid flow devices, including products for lung ventilators and ex-vivo organ and tissue perfusion.

Tellus Therapeutics is a biopharmaceutical company based in Hillsborough, North Carolina, founded in 2018. The company focuses on developing innovative small molecules derived from human maternal breast milk to address unmet medical needs in newborns, particularly those with perinatal brain injury. Its lead drug aims to promote the regeneration of myelin-producing oligodendrocytes and reverse white matter injury in premature infants. By providing effective treatments for all babies at risk of brain injury, Tellus Therapeutics seeks to enhance neurodevelopmental outcomes for these vulnerable children.

North Carolina State University, located in Raleigh, North Carolina, is a prominent educational institution established in 1887. It offers a diverse range of academic programs, granting 106 bachelor's degrees, 104 master's degrees, 61 doctoral degrees, and a Doctor of Veterinary Medicine. The university is renowned for its strengths in science, technology, engineering, and mathematics, as well as in fields such as agriculture and life sciences. It is part of the University of North Carolina system, which encompasses 17 campuses statewide, and serves over 220,000 students. NC State has a significant research presence at the North Carolina Research Campus, focusing on food crops and sustainability. To address environmental concerns, the university launched the University Sustainability Office in 2008. The university is governed by a board of trustees that oversees its assets and operations.

East Carolina University (ECU) is a public doctoral/research institution located in Greenville, North Carolina. Founded in 1907 and formerly known as East Carolina Teachers College, it became East Carolina University in 1951. ECU offers a wide range of undergraduate, graduate, and doctoral programs across various fields, including health sciences, medicine, nursing, music, fine arts, communication, technology, and business. The university is distinguished by its Brody School of Medicine, which ranks highly for its emphasis on primary care and rural medicine. Additionally, ECU provides distance education courses to cater to a diverse student population. The East Carolina University Foundation, established in 1963, manages an endowment fund aimed at enhancing the university's academic programs, research activities, and overall student experience.

The University of North Carolina Wilmington, the state's coastal university, is dedicated to the integration of teaching and mentoring with research and service. University of North Carolina Wilmington, commitment to student engagement, creative inquiry, critical thinking, thoughtful expression and responsible citizenship is expressed in our baccalaureate and master's programs, as well as doctoral programs in areas of expertise that serve state needs. Our culture reflects our values of diversity and globalization, ethics and integrity, and excellence and innovation.

UNC Charlotte is North Carolina's urban research university. It leverages its location in the state's largest city to offer internationally competitive programs of research and creative activity, exemplary undergraduate, graduate and professional programs, and a focused set of community engagement initiatives. UNC Charlotte maintains a particular commitment to addressing the cultural, economic, educational, environmental, health, and social needs of the greater Charlotte region.

The University of North Carolina at Chapel Hill, established in 1789, is the first public university in the United States and operates as a non-profit educational institution. It is dedicated to teaching, research, and public service, serving a diverse community of undergraduate, graduate, and professional students. The university's mission is to foster scholarship and creativity while preparing future leaders to contribute positively to society. With a strong commitment to excellence, it leverages the expertise of its faculty and staff to enhance access to education and promote the success of its students. Additionally, the university manages an endowment fund that supports various initiatives, including scholarships, fellowships, professorships, and research across multiple disciplines. Through its outreach efforts, UNC Chapel Hill aims to improve the quality of life for the citizens of North Carolina and beyond.

Cereius, Inc. is a pre-clinical stage biotechnology company based in Durham, North Carolina, founded in 2017. The company specializes in developing small-molecule therapies aimed at treating brain metastasis, particularly in patients with HER2-positive breast cancer. Cereius employs innovative radiolabeling chemistries that enhance the uptake and retention of radionuclides in target tumors while reducing absorption in normal tissues. This approach significantly improves the therapeutic index and diagnostic contrast of targeting agents, enabling medical practitioners to more effectively treat solid tumor brain metastasis and potentially increase patient survival rates.

Duke BioRepository & Precision Pathology Center (BRPC), Duke’s largest human tissue biobank. BRPC stores samples from consented patients for use in research.

InGateyGen is an agricultural biotechnology company focused on developing and producing hypoallergenic or allergen-reduced peanuts. Utilizing proprietary technologies such as genomics, proteomics, plant tissue culture, and plant propagation, the company aims to create high-value agricultural products that enhance consumer safety and well-being. InGateyGen's commitment to innovation in food science seeks to address the growing demand for allergen-free options, ultimately contributing to improved health outcomes for individuals with peanut allergies.

Isolere Bio is a biotechnology company dedicated to simplifying the purification of biotherapeutics, particularly monoclonal antibodies and Adeno-Associated Viruses (AAV). Co-founded with the aim of enhancing global access to essential drugs, Isolere Bio develops innovative manufacturing technologies that utilize a straightforward Tangential Flow Filtration (TFF) setup. This approach facilitates a seamless transition from laboratory-scale processes to large-scale industrial production, thereby improving efficiency within the bioprocessing industry. As monoclonal antibodies continue to gain prominence as effective therapeutics and important research tools, Isolere Bio's work plays a crucial role in advancing the development of new diagnostics and treatments.

Arrevus, Inc. is a clinical-stage biotechnology company based in Raleigh, North Carolina, focused on developing innovative therapies for orphan diseases, particularly those complicated by antibiotic resistance. Incorporated in 2015, Arrevus has a pipeline that includes several promising candidates: ARV-1801, an oral formulation of fusidic acid aimed at treating pulmonary exacerbations in cystic fibrosis; ARV-1907, an inhaled version of fusidic acid designed for treating persistent staphylococcus aureus lung infections in cystic fibrosis patients; ARV-1502, an engineered inhibitor of bacterial DnaK for cancer treatment; and ARV-1802, a leptin receptor antagonist also targeting cancer. The company is dedicated to addressing critical health issues where existing treatments are limited, particularly in cases where antibiotic resistance poses significant clinical challenges. Through its research, Arrevus aims to enhance treatment options for serious, life-threatening conditions, ultimately improving patient outcomes and quality of life.

Aniluxx Biotechnology, Inc. is a biopharmaceutical company focused on developing innovative topical therapeutics for companion animals, specifically targeting skin diseases such as atopic dermatitis and osteoarthritis. Founded in 2019 and located in Chapel Hill, North Carolina, the company aims to improve the health and well-being of pets by utilizing a pipeline of topically formulated therapeutics based on compounds that have demonstrated safety and efficacy in humans. These therapeutics are designed to be easy to apply and virtually unnoticeable, minimizing the harsh side effects commonly associated with systemic medications. Through its efforts, Aniluxx Biotechnology seeks to provide effective and user-friendly treatment options for dogs, cats, and horses suffering from various skin conditions.

IMMvention Therapeutix is a biotechnology company focused on developing innovative small molecule pan-inflammasome inhibitors aimed at treating inflammatory diseases. The company utilizes a platform technology that leverages biodegradable biopolymeric nano/micro-particles to enhance the immune response. IMMvention Therapeutix specifically targets auto-inflammatory conditions, such as rheumatoid arthritis, osteoarthritis, gout, and Alzheimer's disease, addressing significant unmet medical needs. Its disease-modifying therapies work by inhibiting inflammation triggered by inflammasomes, which are responsible for activating inflammatory responses. In addition to its primary focus, the company also seeks to improve clinical outcomes for patients with other inflammatory conditions, including neuroinflammatory, renal, and metabolic diseases, thereby contributing to the treatment of autoimmune disorders.

Emergo Therapeutics, Inc. is a pharmaceutical company based in Durham, North Carolina, founded in 2016. The company focuses on developing therapeutic drugs aimed at modulating inflammatory cytokines and enhancing immune system function. Its primary product in development is norketotifen, which is intended for the treatment of uncomplicated influenza and flu-like illnesses. Emergo Therapeutics seeks to reduce the production of inflammatory cytokines from mast cells, with a broader goal of addressing various infectious diseases and improving health outcomes related to inflammation.

AveXis, now known as Novartis Gene Therapies, is a biotechnology company focused on developing and commercializing gene therapies aimed at treating rare and life-threatening neurological genetic disorders. Acquired by Novartis in 2018, the company specializes in motor neuron cell-targeted gene replacement therapies for conditions such as spinal muscular atrophy, Rett syndrome, and amyotrophic lateral sclerosis. By addressing these severe diseases, which often result in progressive muscle weakness, paralysis, and death, AveXis plays a crucial role in enhancing treatment options for affected patients and their families.

Redbud Labs, Inc. specializes in the development and manufacturing of MEMS and microfluidics technologies tailored for the life science industry. The company produces actuated surface-attached posts films, which facilitate the manipulation of fluids, cells, and reagents at the microscale, thereby enhancing mixing efficiency and reducing assay times. Additionally, Redbud Labs is known for its innovative MXR, the first fully modular microfluidic mixer, utilized by leading biotechnology firms to enhance assay performance. The company offers cartridge-based automated sample preparation platforms, which simplify laboratory workflows while maintaining high performance. Founded in 2010 and based in Chapel Hill, North Carolina, Redbud Labs draws on advanced research from the University of North Carolina to provide solutions that address complex microfluidic challenges in research, drug discovery, and diagnostics.

TregTherapeutics is a preclinical stage company based in North Carolina, specializing in the development of innovative therapies for multiple sclerosis. The company is focused on creating a tolerogenic vaccine that leverages the regulatory functions of T-regulator cells (Tregs) to modulate the immune response. This approach aims to reverse the inflammatory attacks on the nervous system that characterize multiple sclerosis while promoting an anti-inflammatory response. TregTherapeutics has secured an exclusive license for its proprietary technology from East Carolina University, positioning it to potentially transform treatment outcomes for patients suffering from autoimmune diseases. Its commitment to advancing universal tolerance induction therapy reflects a strategic focus on addressing the underlying causes of neurodegenerative disorders.

Dualogics is a biotechnology company located at the University of North Carolina at Chapel Hill, specializing in the development of bispecific antibodies aimed at treating oncology and autoimmune diseases. Utilizing a proprietary technology, the company engineers new antibody therapeutics, diagnostics, and research tools, resulting in bispecific antibody products that offer enhanced properties compared to traditional methods. Dualogics aims to collaborate with both academic institutions and industry partners to advance a range of multifunctional therapies and reagents, ultimately seeking to improve treatment options for patients affected by these conditions.

InnAVasc Medical specializes in the development of medical devices designed to improve vascular access for hemodialysis. The company focuses on enhancing existing synthetic vascular grafts to ensure safer and more efficient access for dialysis procedures. Their products aim to prevent needle cannulation injuries and improve graft access safety, thus helping healthcare providers minimize the risks of adverse events and device failures that can occur with repeated vascular access. Additionally, InnAVasc addresses the needs of home hemodialysis and immediate access, contributing to overall patient safety and care in the dialysis process.

Avior Bio is a clinical-stage pharmaceutical company focused on developing innovative treatments for neurological conditions and pruritus in patients with liver disease. The company utilizes its proprietary Speedit™ Transmucosal Film Technology, which allows for effective drug delivery by bypassing first-pass metabolism and minimizing the production of glucuronide metabolites excreted by the kidneys. This technology aims to provide significant relief from various symptoms, including insomnia, anxiety, depression, and excoriation. With a strong management team, an experienced advisory board, and dedicated scientists, Avior Bio is well-positioned to deliver safe and effective therapeutic solutions to improve patient outcomes.

Cereius, Inc. is a pre-clinical stage biotechnology company based in Durham, North Carolina, founded in 2017. The company specializes in developing small-molecule therapies aimed at treating brain metastasis, particularly in patients with HER2-positive breast cancer. Cereius employs innovative radiolabeling chemistries that enhance the uptake and retention of radionuclides in target tumors while reducing absorption in normal tissues. This approach significantly improves the therapeutic index and diagnostic contrast of targeting agents, enabling medical practitioners to more effectively treat solid tumor brain metastasis and potentially increase patient survival rates.

Locus Biosciences is a biotechnology company focused on developing a CRISPR-engineered precision antibacterial platform aimed at transforming the treatment of bacterial diseases. The company integrates the antibacterial capabilities of CRISPR-Cas3 technology with the effective and safe delivery of bacteriophages, which are viruses that specifically target bacteria. This innovative approach allows for rapid initiation of treatment by physicians, leading to improved medical outcomes for patients. Through its advanced platform, Locus Biosciences seeks to address the challenges posed by pathogenic bacteria in a precise and targeted manner.

Locus Biosciences is a biotechnology company focused on developing a CRISPR-engineered precision antibacterial platform aimed at transforming the treatment of bacterial diseases. The company integrates the antibacterial capabilities of CRISPR-Cas3 technology with the effective and safe delivery of bacteriophages, which are viruses that specifically target bacteria. This innovative approach allows for rapid initiation of treatment by physicians, leading to improved medical outcomes for patients. Through its advanced platform, Locus Biosciences seeks to address the challenges posed by pathogenic bacteria in a precise and targeted manner.

Baebies, Inc. is a company based in Durham, North Carolina, that specializes in manufacturing screening and pediatric testing equipment for newborns. Founded in 2014 by Richard West and Vamsee Pamula, Baebies developed its newborn screening platform, SEEKER, which is FDA authorized and CE marked. SEEKER enables the simultaneous performance of multiple assays to quantitatively measure the activity of lysosomal enzymes from a single dried blood spot specimen. Additionally, the company produces the FINDER near-patient testing equipment, which also holds CE marking, and the FINDER 1.5 platform, which includes a SARS-CoV-2 test with emergency use notification from the FDA. Baebies utilizes digital microfluidics technology, allowing for efficient diagnostics from low-volume samples, and aims to enhance early disease detection for both children and adults. The company serves hospitals and public health labs, focusing on improving newborn health outcomes and providing innovative diagnostic solutions.

Advanced Chemotherapy Technologies is a healthcare company that is developing breakthrough combination drug-device technologies for treating pancreatic cancer.

Baebies, Inc. is a company based in Durham, North Carolina, that specializes in manufacturing screening and pediatric testing equipment for newborns. Founded in 2014 by Richard West and Vamsee Pamula, Baebies developed its newborn screening platform, SEEKER, which is FDA authorized and CE marked. SEEKER enables the simultaneous performance of multiple assays to quantitatively measure the activity of lysosomal enzymes from a single dried blood spot specimen. Additionally, the company produces the FINDER near-patient testing equipment, which also holds CE marking, and the FINDER 1.5 platform, which includes a SARS-CoV-2 test with emergency use notification from the FDA. Baebies utilizes digital microfluidics technology, allowing for efficient diagnostics from low-volume samples, and aims to enhance early disease detection for both children and adults. The company serves hospitals and public health labs, focusing on improving newborn health outcomes and providing innovative diagnostic solutions.

Dignify Therapeutics LLC is a drug development company based in Durham, North Carolina, that focuses on creating innovative pharmaceutical agents aimed at restoring voluntary control of bladder and bowel functions in patients with spinal cord injuries, spina bifida, multiple sclerosis, and other neurological conditions. Founded in 2013, the company combines novel drug therapies with advanced drug delivery technologies to enhance the quality of life for individuals affected by these disorders. By targeting the specific needs of this patient population, Dignify Therapeutics aims to redefine treatment options and provide effective solutions that enable patients to regain dignity in their excretory functions.

OneFul Health is an e-pharmacy for personalized therapies, combining 3-7 prescription drugs into one small capsule or gel packet. Provide telemedicine physician network connections and home tests for biomarkers and genomic poly-scores to formulate combination treatments with reduced adverse side effects and improved adherence. Founded in 2013 as Panacea BioMatx Inc as a healthcare technology development company. It spun-off Panaceutics.com in 2021, then renamed to OneFul Health to commercialize D2C and B2B personlized pharmaceutical products. Owns accredited pharmacy facilities as its regulatory platform in nine states.

Jenken Biosciences is a specialty pharmaceutical company focused on developing and commercializing innovative small molecules that act as TLR4 antagonists. Targeting the Toll-Like Receptor 4, which plays a crucial role in mediating inflammatory responses, the company aims to address various conditions linked to chronic inflammation, including chronic liver disease, inflammatory bowel disease, cancer, diabetes, and organ damage in the kidneys and lungs. Jenken's drug development strategy emphasizes reducing time-to-market and minimizing risks and costs by re-profiling already approved drugs. Additionally, the company is advancing a diverse pipeline of novel chemical entities aimed at treating chronic liver disease, inflammatory bowel disease, rheumatoid arthritis, and diabetes, as well as addressing organ damage. By leveraging proprietary technology for cytokine modulation, Jenken seeks to restore kidney function affected by various underlying conditions.